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Abstract 
 
Background: Although numerous studies have been undertaken to establish predictive clinical factors associated 
with a higher likelihood of attaining a live birth, there is still no consensus, and its generally discussed only 
specific factors. The aim of the present study was to assess whether any clinical characteristics in intracytoplasmic 
sperm injection cycles are associated with an increased likelihood of live birth delivery. 
 
Methods: Retrospective evaluation of 3844 treatment cycles with intracytoplasmic sperm injection using 
homologous ejaculated sperm. The study was conducted during 11 years (from 2003 to 2014). Cycles were divided 
in two groups according to live birth delivery outcomes: 993 cycles (25.8%) with newborn and 2851 cycles 
(74.2%) without newborn. Comparisons were performed regarding detailed demographic, stimulation, 
embryologic and clinical characteristics. 
 
Results: A higher live birth delivery rate was associated to lower age and lower basal follicle stimulating hormone 
levels; lower total dose of gonadotropins, time of stimulation and dose of human chorionic gonadotropin; higher 
number of follicles and estradiol levels; higher number of aspirated oocytes and mature oocytes, higher rates of 
embryo cleavage, high quality embryos and blastocysts. 
 
Conclusions: Several indicators appeared associated with an increase in the likelihood of live birth, eliciting the 
determination of cut-offs for female age, time of infertility, basal follicle stimulating hormone, estradiol levels, 
number of follicles, retrieved oocytes, mature oocytes, high quality embryos, embryos transferred and the day of 
embryo transfer. Antagonist and agonist protocols, as well as recombinant follicle stimulating hormone and human 
menopausal gonadotropin, gave similar outcomes, and thus the decision for one or another should be patient 
personalized. Spermiogram values did not affect live birth. These findings are thus considered relevant for clinical 
guidance and patient information regarding the likelihood of live birth. 
 
Keywords: Intracytoplasmic sperm injection, Assisted reproductive treatment predictors, Clinical outcomes, 
Newborn outcomes 
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Background 
 
The possibility of fathering for patients with compromised spermiogram values became a reality with the 
development of ICSI (Intracytoplasmic sperm injection) [Swain et al., 1992; van Steirteghem et al., 1993a,b; 
Tesarik and Sousa, 1995]. Although numerous studies have been undertaken to establish predictive clinical factors 
associated with a higher likelihood of attaining a live birth, there is still no consensus [van Loendersloot et al., 
2010]. 
Regarding ovarian stimulation, the recent advances with gonadotropin releasing hormone (GnRH) antagonists 
and agonists elicited the development of personalized stimulation protocols [Huirne et al., 2007]. The subsequent 
appearance of ovarian hyperstimulation syndrome [Sousa et al., 2015] could later be reduced to near zero with 
GnRH agonist ovulation triggering, either associated with a strong luteal supplementation, or followed by embryo 
freezing for later embryo frozen thaw transfer [Humaidan et al., 2011]. In this context, several predictors have 
been raised, such as estradiol levels [Joo et al., 2010], progesterone levels [Kolibianakis et al., 2004], the number 
of follicles [Papanikolaou et al., 2006] and the number of oocytes aspirated [Steward et al., 2014]. Other success 
limiting factors appeared related to the embryo transfer technique [Schoolcraft, 2016], endometrial thickness 
[Kovaks et al., 2003], the number of embryos transferred [Pandian et al., 2013] and the day of embryo transfer 
[Glujosky et al., 2016]. 
Female infertility factors also limit assisted reproductive treatment (ART) outcomes, such as time of infertility 
[Niinimäki et al., 2015], karyotype anomalies, anatomic defects, tumors, tubar pathology, endocrinological 
disarrangements, polycystic ovarian syndrome, endometriosis, immunologic and trombophilic conditions and 
body mass index [Rizk et al., 2008]. Another female limiting factor is ovary aging. The ovarian reserve can be 
predicted based on basal FSH (follicle-stimulating hormone) levels [van Loendersloot et al., 2010], anti-Mullerian 
hormone levels [Reijnders et al., 2016] and antral follicle count [Fleming et al., 2015]. However, ovary aging also 
conditions oocyte quality as, after follicle retrieval, oocytes may be immature [Beall et al., 2010] or dimorphic 
[Rienzi et al., 2011; Sousa et al., 2016]. Morphological inspection of the morphological oocyte is also a critical 
predictive factor, and the use of zona pellucida birefringence and metaphase II plaque positioning, as determined 
by specific optics [Montag et al., 2011], can improve oocyte selection. 
Male infertility factors can also limit ART outcomes, such as karyotype anomalies, Y chromosome 
microdeletions, anatomic defects, tumors, endocrinological disarrangements, epididymis and vasa deferent 
occlusion, and spermatogenesis failure [Nieschlag et al., 2010]. In this context, spermiogram parameters have 
critical predictive importance [Mahat et al., 2016; Pereira et al., 2016], and several methods were developed to 
determine sperm aneuploidy [Nicopoullos et al., 2008], apoptosis [Almeida et al., 2005] and DNA fragmentation 
rates [Sá et al., 2015] to guide clinical decisions. Additionally, several methods were introduced to selectively 
isolate the best sperm for microinjection, such as the use of specific optics [Perdrix and Rives, 2013] and magnetic 
cell sorting [Bucar et al, 2015]. 
Other critical aspects that can influence ART outcomes include the optimization of laboratory ART rooms and 
personnel qualification [Magli et al., 2008; De los Santos et al., 2016], ART technical aspects [Rubino et al., 
2016], the number of metaphase II oocytes, fertilization, embryo cleavage and the number of high quality embryos 
at day 3 [Sousa and Tesarik, 1994; Stoop et al., 2012]. Other important factors have been consistently improved, 
such as those related to embryo cryopreservation, amelioration of embryo culture media, extended embryo culture 
up to the blastocyst stage [Gardner and Lane, 2000; Swain and Smith, 2011; Sousa et al., 2012] and embryo 
dynamics screening [Rubio et al., 2014]. Finally, the use of preimplantation genetic diagnosis [Cooper and 
Jungheim, 2010; Mastenbroek et al., 2011] enabled couples not only to have their children free of diseases but 
also enabled to find and counteract the causes of implantation failures. 
In order to give patients more reliable information and to clinicians better guidelines on the likelihood of 
attaining a live birth, we analysed 3844 ICSI cycles to uncover critical factors, with suggested cut-offs, using 
detailed demographic, stimulation and embryological data. 
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Methods 
Ethics approval 
According to the National Law on Medically Assisted Procreation and the National Council on Medically 
Assisted Procreation guidelines, databases were used after patient informed and written consent. 
Patients 
Retrospective evaluation of 3844 treatment cycles using homologous ejaculated sperm and ICSI. Seropositive, 
anejaculation, retrograde ejaculation, preimplantation genetic diagnosis and Y chromosome microdeletions cases 
were excluded. The period of analysis was between 25-09-2003 and 17-01-2014 (11 years). 
Karyotype analysis 
Karyotypes were evaluated using G-banding with analysis of at least 30 metaphases from peripheral blood 
lymphocytes, according to general protocols [Rooney and Czepulkowski, 1997]. There were 10 Klinefelter cases 
(3 NB from 3 distinct cases). 
Stimulation Protocol 
Women underwent controlled ovarian hyperstimulation with a GnRH antagonist protocol in 92.2% of the cases 
(Merck Serono, Geneve, Switzerland; Organon, Oss, Netherlands) and with an agonist protocol in 7.8% of the 
cases (Sanofi Aventis, Frankfurt, Germany). For stimulation, recombinant follicle stimulating hormone (rFSH) 
was used in 56.4% of the cases (Organon; Merck Serono); human menopausal gonadotropin (HMG) was added 
to rFSH in 42.9% of the cases (Ferring, Kiel, Germany); and only HMG in 0.7% of the cases. Ovulation trigger 
was performed with human chorionic gonadotropin (HCG) in 79.8% of the cases (Organon); with recombinant 
HCG in 18.9% of the cases (Merck-Serono); and with a GnRH agonist in 1.3% of the cases (Sanofis, Aventis, 
Frankfurt, Germany; Ipsen Pharma Biotech, Signes France). Estradiol serum levels were assayed at the day of 
HCG or one day before [Huirne et al., 2007; Pinto et al., 2009]. 
Gamete and Embryo Handling 
Media from Medicult (Jyllinge, Denmark) or Vitrolife (Kungsbacka, Sweden) were used. Microinjection was 
performed in a Hoffman optics inverted microscope (Nikon, Tokyo, Japan) equipped with Narishige 
micromanipulators (Tokyo, Japan), using Swemed micropipettes (Goteborg, Sweden) and under a described 
technique [Tesarik and Sousa, 1995]. Embryo quality was evaluated according to described methods [Vandervorst 
et al., 1998; Gardner et al., 2000]. Ultrasound-guided embryo transfer used a Sure View Wallace Embryo 
Replacement Catheter or Wallace malleable stylet (Smiths Medical Int, Kent, UK). 
Luteal Supplementation 
All patients had luteal supplementation with intravaginal administration of natural-micronized progesterone 
(Jaba, Besins Int, Montrouge, France; Effik, Bievres, France), from the day of oocyte retrieval. Implantation was 
confirmed by a rise in β-HCG serum twelve days after embryo transfer. Clinical pregnancy was established by 
ultrasound at seven weeks of gestation. When a GnRH agonist was used for triggering final oocyte maturation, 
luteal support was associated with oral estradiol (Novo Nordisk, Bagsvaerd, Denmark) and HCG (1500 IU) at the 
day of oocyte pick-up [Radesic and Tremellen, 2011]. 
Statistical Analysis 
For statistical analysis the IBM SPSS Statistics 22 program for Windows was used. Means were compared 
using t-Test for independent samples. Categorical variables were analysed using descriptive statistics and Chi 
square test, with continuity correction. All statistical tests were two-tailed, with significance level of 0.05 (p 
<0.05). 
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Results 
Patients and study groups 
The 3844 ICSI cycles were divided in two groups according to their outcomes and compared regarding 
demographic, stimulation, embryologic, clinical and newborn (NB) characteristics: 993 cycles (25.8%) with NB 
and 2851 cycles (74.2%) without NB. 
Demographic characteristics 
Regarding demographic characteristics (Table 1), the NB group showed a significant lower mean female and 
male ages, a similar time of infertility, a significant higher number of cases with pure male factor and a significant 
lower number of cases with pure female and mixed infertility factors, and a significant lower mean level of basal 
FSH (bFSH). There were no significant differences regarding female and male karyotypes. The prevalence of 
chromosome abnormalities in the general population is about 0.5-1% [Turnpenny and Ellard, 2012]. The present 
results thus confirm that the rate of abnormal karyotypes is higher in infertile individuals [Sousa et al., 2016; 
Gekas et al., 2001]. 
Stimulation characteristics 
Regarding stimulation characteristics (Table 1), the NB group manifested a significant lower mean total dose 
of gonadotropins and HCG used; a lower mean time of stimulation; a higher mean number of developed ovarian 
follicles; and higher mean serum estradiol (E2) levels. 
Embryological and clinical outcomes 
As expected, regarding embryological and clinical outcomes, the NB group (Table 2) showed significant 
higher mean values for all parameters analysed, which included the number of oocytes retrieved (COC), mature 
metaphase II oocytes (MII), fertilization rate (FR), embryo cleavage rate, high grade embryos at day 3, blastocyst 
rate, implantation rate (IR), biochemical (BP), clinical (CP) and ongoing (OP) pregnancy rates, without any cases 
of ectopic pregnancy or abortion. 
Newborn outcomes 
The characteristics of NB are given in Table 2 and Table 3. The rate of NB malformations was 1.3%, 1% 
major and 0.3% minor (Table 2). These rates are quite lower regarding population studies that revealed 2-5% of 
major and 10% of minor NB malformations [Turnpenny and Ellard, 2012]. About 80% of the NB had a term 
gestation and 65% a normal weight (Table 3). 
Subgroup analysis 
To uncover some thresholds on the likelihood of achieving a live birth deliver (LBD), several characteristics 
were analysed: female age, time of infertility, stimulation protocol, gonadotropins, follicles, number of retrieved 
COC, mature MII, high quality embryos, number of embryos transferred, day of embryo transfer, and sperm 
concentration, rapid progressive motility and normal morphology (Figs. 1-3). 
The female age was divided into six stages (Fig. 1). The NB group showed a significant lower number of cases 
with ≥ 40 years, and no significant differences were observed in the younger stages. Most of the successful cases 
were found in women with < 35 years (61%) and < 39 years (89%) (Fig. 1 left). Results evidenced a continuous 
decrease in the likelihood of LBD with advancing female age, with the higher likelihood of LBD belonging to the 
age stages of < 30 years and 30-35 years (Fig. 1 right). 
The time of infertility was divided into four stages (Fig. 1). No significant differences were observed except 
when the time of infertility was < 5 years (Fig. 1 left). Results evidenced a continuous decrease in the likelihood 
of getting a successful pregnancy with advancing time of infertility, with the higher likelihood of achieving a LBD 
being observed with < 5 years of infertility (Fig. 1 right).  
Regarding the stimulation protocol the differences found were significant. The antagonist protocol was used 
in 90% of the cycles in the NB group and in 93% of the cycles in the no-NB group; whereas the agonist protocol 
was used in 10% of the cycles in the NB group and in 7% of the cycles in the no-NB group 187 (Fig. 1 left). 
Results evidenced a higher likelihood of attaining a LBD with the agonist protocol (Fig. 1 right). 
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In relation to gonadotropins, the NB group evidenced a significant higher number of cases that used only rFSH 
and a significantly lower number of cases where both rFSH and HMG were used, with no significant differences 
regarding the sole use of HMG (Fig. 1 left). There was a decrease in the likelihood of achieving a LBD from the 
use of rFSH, to rFSH+HMG and then to HMG, with the highest likelihood of LBD being observed in cases where 
only rFSH was used (Fig. 1 right). 
For the analysis of follicles we divided cycles in 6 intervals (Fig. 1). Most of the successful cases presented 
>4 follicles (Fig. 1 left). The likelihood of a successful LBD increased with the number of follicles, being 
significantly lower when <4 follicles and between 4-9 follicles, and higher between 10-13 and 14-18 follicles 
(Fig. 1 right). 
The number of retrieved COC was divided in six intervals (Fig. 2). The NB group showed a significant higher 
number of cases with 4-9 COC and 4-15 COC, a significant lower number of cases with ≤3 COC, and no 
significant differences when there were >10 COC retrieved, with most of the cases with NB presenting 4-15 COC 
(Fig. 2 left). There was a lower likelihood of LBD with ≤3 COC and a progressive higher likelihood of LBD up 
to 15 COC retrieved (Fig. 2 right). 
The number of MII was divided in six intervals (Fig. 2). The NB group presented 4-9 MII in the majority of 
the cases, a significant lower number of cases with ≤3 MII and a significant higher number of cases with 4-15 
MII, with no significant differences in the other intervals (Fig. 2 left). The likelihood of LBD was lower with ≤3 
MII and progressively higher up to 15 MII (Fig. 2 right). 
The number of high quality embryos at day 3 (AB) was divided in two groups (Fig. 2). The NB group showed 
a significant lower number of cases with <3 AB and a significant higher number of cases with ≥3 AB (Fig. 2 left). 
The likelihood of LBD was lower when <3 high quality embryos were obtained and higher in cases with ≥ 3AB 
(Fig. 2 right). 
The number of embryos transferred was divided in four groups (Fig. 2). The NB group evidenced a significant 
lower number of cases with transfer of 1 or 3 embryos, and a significant higher number of cases with transfer of 
2 embryos (Fig. 2 left). The likelihood of LBD decreased with the number of embryos transferred, being higher 
with transfer of 2 embryos (Fig. 2 right). 
The day of embryo transfer was divided in five groups (Fig. 2). The NB group showed a significant higher 
number of cases with embryo transfer performed at day 5, and a significant lower number of cases with embryo 
transfer performed at day 2 and day 3 (Fig. 2 left). The likelihood of LBD increased with the day of embryo 
transfer, and was higher at day 5 (Fig. 2 right). 
Sperm concentration, rapid progressive motility and normal morphology were divided in five intervals (Fig. 
3). For normal morphology, although the NB group presented ≥ 20 M sperm/ml in the majority of the cases, with 
significance attained with ≥ 5M sperm/ml (Fig. 3 left), the likelihood of LBD decreased with sperm concentration 
(Fig. 3 right). For rapid progressive motility, although in the NB group the majority of cases presented ≥ 10%, 
with significance attained when ≥ 5% (Fig. 3 left), the likelihood of LBD decreased with sperm rapid progressive 
motility (Fig. 3 right). For normal morphology, although the NB presented ≥5% in the majority of the cases, with 
significance observed when <5% (Fig. 3 left), the likelihood of LBD was independent of sperm normal 
morphology (Fig. 3 right). Regarding clinical subgroups, although the NB group showed a significant higher 
number of teratozoospermia cases (Fig. 3 left), the likelihood of LBD was independent of clinical spermiogram 
classifications (Fig. 3 right). 
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Discussion 
Several factors can influence pregnancy outcomes in ICSI cycles with ejaculated sperm. In this report of 3,844 
cycles the LBD was associated with lower couple ages, time of infertility, bFSH levels, time of stimulation, total 
dose of gonadotropins and HCG dose, and with a higher mean number of follicles and E2 levels. Regarding 
embryological and clinical outcomes, LBD was associated with a higher mean number of COC, MII, cleaved 
embryos, high quality embryos and blastocysts. Bellow, the relative predictive value of the main factors analysed 
in the present report are discussed. 
Regarding female age, the present results showed a decline in the likelihood of LBD after 30 years, with 
significant differences found in women < 35 years, < 39 years and ≥ 40 years. Results confirm previous studies, 
albeit with a lower number of cycles. One study showed that the likelihood of CP decreased progressively with 
female age [Ottosen et al., 2007]. Another work evidenced that the chance of achieving a CP in women < 30 years 
is 3.2 higher, between 30-34 years is 2.8 higher and with < 35 years is 2.5 higher [Sabatini et al., 2008]. Another 
study showed that the CP rate increases up to 30 years, then slowly decreases and finally sharply decreases when 
≥ 40 years. In that report, women of 30 years were 1.5 times more likely to become pregnant, women with 35 
years had a similar chance, and 40 years old women had 4 times lower expectancy [Pinto et al., 2009]. Finally, a 
meta-analysis indicated that increasing female age was associated with lower CP rates [van Loendersloot et al., 
2010]. Taking into account those observations and results of our large series, female age can be used as a predictive 
factor for LBD, with an upper cut-off of 35 years.  
In relation to the time of infertility, results showed a decline in the likelihood of LBD after 2 years of 
infertility. In accordance, though with a lower number of cycles, other authors observed that the likelihood of CP 
decreased after 1 year of infertility [Ottosen et al., 2007]. A meta-analysis also confirmed that OP rates decreased 
with the time of infertility [van Loendersloot et al., 2010]. Based on results from our large series and on those 
cited above, the time of infertility can be used as predictive factor for LBD, with a positive cut-off of < 2 years 
and a negative cut-off of > 5 years. The levels of bFSH were significantly lower in the NB group, which reflects 
the higher capacity of the ovary for follicle growth in younger women. Several previous studies, regardless of a 
lower number of cycles, showed that when bFSH levels are > 10 IU/L, the embryological, clinical and NB 
outcomes are significantly decreased [Ottosen et al., 2007; Sabatini et al., 2008; Abdalla and Thum., 2004; Thum 
et al, 2009]. Based on the present results, on those studies cited above and on a recent meta-analysis [van 
Loendersloot et al., 2010], bFSH levels can be used as a predictive factor of LBD, with an upper cut-off of 10 
IU/L. 
The GnRH antagonist protocol was used in the large majority of the cases, but the likelihood of LBD 
significantly favoured the agonist protocol. Previous studies showed that the antagonist protocol was associated 
with lower time of stimulation, higher number of COC, MII, high quality embryos and embryo cleavage rate, 
whereas the agonist protocol exhibited a higher FR, with no significant differences between both protocols 
regarding the rates of BP, CP, implantation and LBD [Pinto et al., 2009]. Although there is a general consensus 
that the antagonist protocol is devoid of side effects, enables lower time of stimulation, gonadotrophin dose and 
risk of ovarian hyperstimulation syndrome (OHSS), other reports debate that the agonist protocol is associated 
with better embryological and clinical outcomes [Kolibianakis et al., 2006; Al-Inany et al, 2016]. Taking into 
account these previous studies, differences between both protocols should be considered marginal and clinically 
irrelevant, and the decision of using one or another stimulation protocol should rely on individual patient 
characteristics. 
Regarding gonadotropin stimulation, results showed that the use of rFSH is significantly associated with 
higher LBD than the combination of rFSH with HMG or the use of HMG. Previous studies revealed distinct 
results. Cochrane reviews indicated that HMG was associated with higher rates of CP and LBD than rFSH [van 
Wely et al., 2011]. Another report showed that although HMG was associated with higher female age, bFSH levels 
and total dose of gonadotropins, and lower E2 levels, COC, MII, cleaved embryos and high quality embryos, it 
exhibited similar rates of implantation, CP and LBD to rFSH [Shavit et al., 2016]. Based on results and those of 
the above reports, differences between rFSH and HMH should be considered marginal and clinically irrelevant, 
and the decision of using one or another stimulation protocol should rely on individual patient characteristics. 
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The levels of E2 were significantly higher in the NB group, which was associated with a higher number of 
follicles. Previous studies showed that although the CP rate was not affected by E2 levels of normal responders 
(<2500 pg/ml) or high responders (>2500 pg/ml) [Papageorgiou et al., 2002], the rates of LBD increased with E2 
levels, with the better LBD rates being achieved with 3000-4000 pg/ml E2 for women <38 years and 279 2000-
3000 pg/ml E2 for women >38 years [Joo et al., 2010]. This is in line with the defined upper cut-off for an 
increased risk of OHSS, which is 4500 pg/ml [Sousa et al., 2015]. Thus, E2 levels can be used as a predictive 
factor for LBD, with a cut-off of 2000-4000 pg/ml. In relation to the mean number of follicles, results suggested 
a lower likelihood of LBD with ≤4 follicles and a progressive higher likelihood of LBD from 4 to 18 follicles, 
with the maximized LBD attained in the interval 14-18 follicles. Although unable to find similar studies for 
comparisons, an upper limit of 14 follicles and a lower cut-off of 4-9 follicles are suggested. The number of 
follicles is related to the development of OHSS. In the NB group, of the 4 cases (0.4%) where an agonist was used 
for oocyte trigger due to risk of OHSS, 2 cases had > 18 follicles. However, in the no-NB group, of the 43 cases 
(1.5%) that used an agonist, 32 (74.4%) had >18 follicles, and with ≤14 follicles this risk decreased to 7 cases 
(16%). These results are reinforced by previous studies that showed an increased risk of OHSS when the number 
of follicles was >18 [Sousa et al., 2015; Papanikolaou et al., 2006]. The mean number of retrieved cumulus-
oocyte complexes has been used to define women as poor (≤3 COC), normal (4-9 COC) or high (≥15 COC) 
responders [Polyzos et al., 2014; Polyzos and Sunkara, 2015], with the observance of an increased risk of OHSS 
when ≥15 COC were retrieved [Sousa et al., 2015]. The present results confirmed the low likelihood of LBD when 
≤3 COC were retrieved and a higher likelihood of LBD from 4 to 15 COC, with the maximized LBD attained in 
the interval 10-15 COC. This is in accordance with cut-off suggested by other authors: 15 COC [Sunkara et al., 
2011], 8-15 COC [Cai et al, 2013] and 10-15 COC [Steward et al., 2014]. Results suggest that the mean number 
of follicles can be used as a predictive factor for LBD, with a cut-off of 4-15 COC. 
In relation to the number of MII, the present results confirmed the low likelihood of LBD when ≤ 3 MII were 
obtained, and a progressive higher likelihood of LBD from 4 to 15 MII, with the maximized LBD attained in the 
interval 10-15 MII. Although unable to find similar studies for comparison, previous studies evidenced that the 
number of MII is positively correlated with LBD [Cai et al., 2011]. Results suggest that the mean number of MII 
can be used as a predictive factor for LBD, with a cut-off of 4-15 MII. Previous studies revealed that the number 
of high quality embryos at day 3 is a critical predictive factor, but a relevant cut-off was not offered. Those 
authors observed that the transfer of high quality embryos increased the CP rate [Ottosen et al., 2007; Cai et al., 
2011], the rates of CP and LBD [Dennis et al., 2006], or the LBD rate [Niinimäki et al., 2015]. The present results 
showed that the likelihood of LBD increased with the number of high quality embryos, being higher when ≥ 3, 
which indicates that the number of high quality embryos can be used as a predictive factor for LBD, with a cut-
off of ≥ 3 high quality embryos. 
In relation to the number of embryos transferred, the present results showed the transfer of 1 or 3 embryos 
was associated with a significant lower LBD, with the likelihood of LBD being higher when 2 embryos were 
transferred. Results also revealed that single blastocyst transfer was associated with no multiple pregnancies and 
35% of LBD, whereas double blastocyst transfer presented 20% of twin pregnancies and 44% of LBD. On the 
other hand, single embryo transfer at day 3 was associated with no multiple pregnancies and 17% of LBD, whereas 
double embryo transfer at day 3 presented 9% of twin pregnancies and 30% of LBDR. This confirms previous 
studies, which indicated that although single embryo transfers decreased the LBD rate it also reduced the risk of 
multiple pregnancies, and that with the subsequent replacement of a single frozen embryo the LBD rate became 
comparable to double embryo transfer [Pandian et al., 2013; Baruffi et al., 2009; Martikainen et al., 2001; Pandian 
et al., 2005]. The present results and those of previous studies evidence that the number of embryos transferred 
can be used as a predictive factor for LBD, with a cut-off of 1-2 embryos. Results also indicate that in cases of 
blastocyst transfer a single embryo transfer should be the first choice. The clinical decision on transfer of two 
embryos at day 2 or 3 is frequently dependent on the lower LBD, as 2-3 subsequent replacements of a single 
frozen embryo would be needed to give patients an acceptable LBD per cycle. 
Regarding the day of embryo transfer, the present results showed a significant increase in the likelihood of 
LBD with the day of embryo transfer, with the maximum being attained at day 5. This confirms previous reports 
of randomized controlled clinical trials [Papanikolaou et al., 2008] and Cochrane reviews [Glujosky et al., 2016], 
which showed higher LBD with blastocyst transfer. The present results and those of previous studies evidence 
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that the day of embryo transfer can be used as a predictive factor for LBD, and suggest that the preferable day for 
embryo transfer is day 5, as blastocysts elicit a significant higher LBD rate. 
Evaluation of sperm parameters revealed that sperm concentration, rapid progressive motility and 
morphology had no clinical impact in the likelihood of achieving a LBD. These observations confirm previous 
studies, which showed that severe teratozoospermia [French et al., 2010] or decreased sperm concentration and 
progressive motility [Zheng et al., 2016] had no negative impact on clinical outcomes. Those studies suggested 
that these apparently strange observations might be due to the strict sperm preparation method and selection for 
microinjection. Nevertheless, from the present results and those of previous studies it is indicated that sperm 
parameters have no negative impact on clinical outcomes and cannot be used as a predictive factor for LBD. 
 
Conclusions 
The present results, using a large number of cases (3844 cycles) with microinjection of ejaculated sperm, 
indicated that LBD is associated with several demographic and stimulation variables such as younger age, more 
pure male infertility factors, lower bFSH, total gonadotropin dose, time of stimulation and HCG dose, and higher 
number of follicles and estradiol levels. Regarding embryological outcomes, the LBD was associated with 
significantly higher mean number of COC, MII, cleaved embryos, high quality embryos and blastocysts. Data 
from the present results and that of previous studies suggest the following indicators (cut-off) that appeared 
associated with an increased likelihood of LBD: female age ≤ 35 years; time of infertility ≤ 5 years (ideal < 2 
years); bFSH ≤ 10 IU/L; both the antagonist and agonist protocols, as well as rFSH and HMG, gave similar 
outcomes, and thus the choice should be individualised; E2 levels 2000-4000pg/ml; number of follicles ≥ 4 (ideal 
maximum of 14 follicles); number of COC ≥ 4 (ideal maximum of 15 COC); number of MII ≥ 4 (ideal maximum 
of 15 MII); number of high quality embryos ≥ 3; double embryo transfer at day 3, single embryo transfer at day 
5; and no relation between spermiogram values and LBD. These findings are thus considered relevant for clinical 
guidance and patient information regarding the likelihood of LBD. 
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ANEXOS 
 
Legend to Figures 
 
Left panel. Percentage of cycles with NB (dark box) and without NB (light box). This percentage was calculated 
within each group independently using the total of 993 cycles for the NB group and the total of 2,851 cycles for 
the no-NB group. 
 
Right panel. Percentage of cycles with NB (dark box) and without NB (light box). This percentage was calculated 
using the total number of cycles in each grade (with NB + without NB). The linear tendency line and the linear 
regression (R2) indicate the likelihood of achieving a live birth. 
 
Female age, Time of infertility (years); 
Ag: Agonist protocol; 
Antag: Antagonist protocol; 
COC: Cumulus-oocyte complexes (retrieved oocytes); 
MII: Mature metaphase II oocytes; 
AB: High quality embryos at day 3; 
Nº ET: Number of embryos transferred; 
ET day: day of embryo transfer; 
Conc: sperm concentration (M/ml); 
RPM: sperm rapid progressive motility (%); 
NM: sperm normal morphology (%); 
O: oligozoospermia; 
A: asthenozoospermia; 
T: teratozoospermia. 
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Table 1. 
 
 
 
Significance (p < 0.05).  
Comparisons as: 
a = Total cycles vs cycles with NB. 
b = Total cycles vs cycles without NB. 
c = cycles with NB vs cycles without NB. 
NS: not significant.  
 
NB newborn, bFSH basal follicle stimulating hormone, Total dose total gonadotropin dose, HCG human chorionic 
gonadotropin.  
 
  
TABLE 1 - Demographic and stimulation characteristics. ICSI cycles using ejaculated sperm 
Variable  Total with NB without NB p 
Cycles (n) 3844 993 2851  
Female age (y) (mean ± SD) 35.41 ± 4.49  33.46 ± 3.76  36.09 ± 4.52  a-b-c 
Male age (y) (mean ± SD) 36.92 ± 5.73  35.46 ± 5.24  37.43 ± 5.81  a-b-c 
Time infertility (y) (mean ± SD) 3.25 ± 2.70  3.18 ± 2.52  3.27 ± 2.76  NS 
Male factor (rate) 72.4 77.6 70.5 a-c 
Female factor (rate) 4.5 2.5 5.2 a-c 
Mixed factors (rate) 23.1 19.9 24.3 a-c 
Abnormal female karyotype (rate)  2.5 2.7 2.5 NS 
Abnormal male karyotype (rate) 2.4 1.7 2.8 NS 
bFSH (IU) (mean ± SD) 7.42 ± 3.71  6.59 ± 2.52  7.71 ± 4.01  a-b-c 
Follicles (mean ± SD) 10.93 ± 6.45  12.99 ± 5.84  10.22 ± 6.50  a-b-c 
Total dose (IU) (mean ± SD) 2195.30 ± 1132.29  1779.37 ± 824.01  2340.27 ± 1187.97  a-b-c 
Time stimulation (days) (mean ± SD) 8.53 ± 1.86  8.37 ± 1.50  8.58 ± 1.97  a-c 
Estradiol (pg) (mean ± SD) 1281.10 ± 955.29  1365.17 ± 740.14  1250.43 ± 1020.99  a-c 
HCG dose (IU) (mean ± SD) 9025.79 ± 2070.44  8552.56 ± 2134.67  9201.69 ± 2018.38  a-b-c 
Busereline (IU) (mean ± SD) 0.80 ± 0.00 (n=47) 0.80 ± 0.00 (n=4) 0.80 ± 0.00 (n=43) b 
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Significance (p < 0.05).  
Comparisons as: 
a = Total cycles vs cycles with NB. 
b = Total cycles vs cycles without NB. 
c = cycles with NB vs cycles without NB. 
NS = not significant.  
 
NB newborn, COC cumulus-oocyte complexes (aspirated oocytes), MII mature oocytes at metaphase II of meiosis, 
2PN-2PB normal fertilized oocytes (with 2 pronuclei and 2 polar bodies), OP ongoing pregnancy, LBDR live-
birth delivery rate, EN death early neonatal death.  
 
  
TABLE 2 - Embryological and clinical outcomes. ICSI cycles using ejaculated sperm 
Parameters Total with NB without NB p 
Cycles (n) 3844 993 2851  
Embryo transfer cycles (n) 3334 993 2341  
COC (n, mean ± SD) 26581 (6.91 ± 4.83)  8554 (8.61 ± 4.42)  18027 (6.32 ± 4.83)  a-b-c 
MII (n, rate) 20818 (5.9)  6948 (7.0)  13870 (5.4)   
Maturation rate (MII/COC) (rate) 78.3 81.2 76.9 a-b-c 
2PN/2PB (n, rate) 16068 (4.7)  5569 (5.6)  10499 (4.3)   
Fertilization rate (2PN/MII) (rate) 77.2 80.2 75.7 a-b-c 
Embryos cleaved-day 2 (n, rate) 15938 (4.6)  5555 (5.6)  10383 (4.2)   
Embryo cleavage rate (d2/2PN) (rate) 99.2 99.7 98.9 a-b-c 
Day 3 embryos (n, rate) (n, rate) 11409 (4.2)  4304 (4.8)  7105 (3.9)   
Day 3 grade A/B embryos (n, rate) 10891 (4.0)  4146 (4.7)  6745 (3.7)   
Day 3 grade A/B rate (rate) 95.5 96.3 94.9 a-c 
Day-4 embryos (n, rate) 5695 (3.9)  2469 (4.3)  3226 (3.7)   
Day-5 embryos  (n, rate) 4355 (3.5)  1917 (3.9)  2438 (3.3)   
Blastocyst rate (rate) 47.6 52.4 44.4 a-b-c 
nº of transferred embryos (n, mean ± SD) 6211 (1.86 ± 0.51)  1896 (1.90 ± 0.39)  4315 (1.84 ± 0.55)  a-c 
Biochemical pregnancy (/ETC) (n, rate) 1354 (40.6) 990 (99.7) 364 (15.5)  
Sacs (n) 1534 1304 230  
Implantation rate (nº sacs/nº ET) (rate) 24.7 68.8 5.3  
Clinical pregnancy (/ETC) (n, rate) 1221 (36.6) 993 (100) 228 (9.7)  
Singletons (/CP) (n, rate) 863 (70.7) 685 (69) 178 (78.1)  
Twins (/CP) (n, rate) 331 (27.1) 305 (30.7) 26 (11.4)  
Triplets (/CP) (n, rate) 3 (0.2) 3 (0.8) 0  
Ectopic pregnancy (/CP) (n, rate) 24 (2.0) 0 24 (10.5)  
Abortion (/CP) (n, rate) 204 (16.7) 0 204 (89.5)  
OP (/ETC)-(CP-Ab-Ect) (n, rate) 993 (29.8) 993 (100) 0  
Delivery (/ETC) (n, rate) 984 (29.5) 984 (99.1) 0  
Stillborn (n) 3 3 0  
LBDR (/ETC)-(Delivery-Stillborn) (n, rate) 981 (29.4) 981 (98.8) 0  
Newborn (/ETC): (n, rate): 1234 (37.0) 1234 (100) 0  
Male (/NB)  638 (52.0) 638 (52)   
Female (/NB)  588 (48.0) 588 (48.0)   
M/F ratio 1.2 1.2   
NB malformations (/NB): (n, rate): 16 (1.3) 16 (1.3)   
Major (/NB)  12 (1.0) 12 (1.0)   
Minor (/NB)  4 (0.3) 4 (0.3)   
ENdeath (/ETC) (n) 0 0   
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NA not applicable. 
 
 
  
TABLE 3 - Newborn outcomes. ICSI cycles using ejaculated sperm 
Parameters Total with NB without NB p 
Cycles (n) 3844 993 2851 NA 
Embryo transfer cycles (n) 3334 993 2341  
Newborn (n) 1234 1234 -  
Gestation age (weeks) (mean ± SD) (n) 37.7  ± 2.8 993    
Term (weeks) (mean ± SD) (rate, n) 38.7 ± 1.1 (79.7) 791   
Preterm (PT) (weeks) (mean ± SD) (rate, n) 33.5 ± 3.3 (20.0) 198   
Very PT (weeks) (mean ± SD) (rate, n) 28.0 ± 3.2 (4.1) 41   
Extremely PT (weeks) (mean ± SD) (rate, n) 23.80 ± 2.3 (1.2) 12   
Weight (g) (mean ± SD) (n) 2739.7 ± 703.3 1204   
Normal weight (g) (mean ± SD) (rate, n) 3111.4 ± 357.5 (65.4) 788   
Low weight (LW) (g) (mean ± SD) (rate, n) 1943.6 ± 490.0 (33.1) 399   
Very LW (g) (mean ± SD) (rate, n) 1102.4 ± 269.0 (6.3) 76   
Extremely LW (g) (mean ± SD) (rate, n) 790.6 ± 172.2 (2.2) 26   
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